For every one of the ASX Biotech Success Stories, there are several failures. While a handful of companies can and do convert clinical data into extraordinary value, many others run into the barrier that decides everything: the primary endpoint. The successes tend to follow a recognisable pattern — a credible clinical signal, external validation, and either…